← Leaderboards
Juhienah Khalaf
Inimmune Corporation
$3,072,270
Attributed
$3,072,270
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2018–21$2M$1.5M$1M$500K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$3,072,270 · 4
By mechanism
N44$1,836,453 · 1
R44$1,017,317 · 1
R43$176,807 · 1
N43$41,693 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Tlr4 Gene”
- Jay Evans · University Of Montana$11,863,882
- Ian R Lanza · Mayo Clinic Rochester$4,737,809
- Suchismita Acharya · Ayuvis Research, Inc.$4,447,445
- Mohamed Abdel Mohsen · Wistar Institute$3,891,229
- Yakov Kogan · Kadvax Technologies, Inc.$3,663,514
- Merlin L Robb · Henry M. Jackson Fdn For The Adv Mil/Med$2,853,934
Research focus
Tlr4 GeneAgonistFormulationReporterBiologicalPeripheral Blood Mononuclear CellIn VivoStructure-Activity RelationshipFrancisella TularensisAqueousExposure ToEvaluationAnalogHourChikungunyaAdenovirusesEmbryoBioterrorismBunyaviridaeBurkholderia PseudomalleiCandidiasisAntiviral AgentsCellsBiological Products
Grant awards (5)
Development of a new TLR4 agonist for the treatment of Allergic Rhinitis$1,836,453
N44 · FY2021 · AI · contact PI
Novel synthetic TLR4 agonists$580,244
R44 · FY2020 · AI · contact PI
Novel synthetic TLR4 agonists$437,073
R44 · FY2019 · AI · contact PI
Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis$41,693
N43 · FY2019 · AI · contact PI
Novel synthetic TLR4 agonists$176,807
R43 · FY2018 · AI · contact PI